Most patients can discontinue antidepressants without severe problems, while some experience significant withdrawal symptoms such as anxiety, dizziness, and sensory disturbances. These symptoms, which often occur in the final stages of tapering, should not automatically be interpreted as a relapse of the underlying condition. Healthcare professionals must adopt a reassuring yet non-minimizing approach, providing clear, balanced information to normalize the process and reduce nocebo effects. Personalized tapering strategies, including gradual dose reductions based on hyperbolic curves or the so-called 10 procent rule, can ease the transition. More evidence-based examples of successful tapering methods are needed to support patients effectively through this challenging phase.